Literature DB >> 6428981

Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.

C W Howden, J A Forrest, J L Reid.   

Abstract

The effects of omeprazole, a substituted benzimidazole, on gastric acid and pepsin secretion have been studied in twelve healthy subjects. From six to eight hours after a single oral dose of 30 mg, there was a 66% reduction in basal acid output, and a 71.2% reduction in pentagastrin stimulated acid output. A single dose of 60 mg produced a 91.7% reduction in basal acid output and a 95.3% reduction in pentagastrin stimulated acid output. After seven days treatment with 30 or 60 mg daily, there was almost 100% inhibition of both basal and pentagastrin stimulated acid output. Omeprazole did not significantly affect pepsin secretion which is in keeping with its proposed mode of action, as an inhibitor of the H+/K+-ATPase enzyme on the secretory membrane of the parietal cell. There were no side effects after omeprazole either with single or repeated dosing.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428981      PMCID: PMC1432608          DOI: 10.1136/gut.25.7.707

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

Authors:  W L Burland; W A Duncan; T Hesselbo; J G Mills; P C Sharpe; S J Haggie; J H Wyllie
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

2.  A modified hemoglobin substrate method for the estimation of pepsin in gastric juice.

Authors:  A Berstad
Journal:  Scand J Gastroenterol       Date:  1970       Impact factor: 2.423

3.  Positioning of subject and of nasogastric tube during a gastric secretion study.

Authors:  M A Hassan; M Hobsley
Journal:  Br Med J       Date:  1970-02-21

4.  Continuous intravenous pentagastrin as a stimulant of maximal gastric acid secretion.

Authors:  M C Mason; G R Giles; C G Clark
Journal:  Gut       Date:  1969-01       Impact factor: 23.059

5.  Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazole.

Authors:  K Oberg; H Lindström
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

6.  Control of acute Zollinger-Ellison syndrome with intravenous omeprazole.

Authors:  A Blanchi; J C Delchier; J C Soule; D Payen; J P Bader
Journal:  Lancet       Date:  1982-11-27       Impact factor: 79.321

7.  Effect of repeated, once daily, oral omeprazole on gastric secretion.

Authors:  P Müller; H G Dammann; H Seitz; B Simon
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

8.  Basal gastric secretion: reproducibility and relationship with duodenal ulceration.

Authors:  R G Faber; M Hobsley
Journal:  Gut       Date:  1977-01       Impact factor: 23.059

9.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

10.  Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. A new H2-receptor antagonist.

Authors:  N R Peden; J H Saunders; K G Wormsley
Journal:  Lancet       Date:  1979-03-31       Impact factor: 79.321

View more
  34 in total

1.  Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion.

Authors:  I Berlin; P Molinier; A Duchier; A Cournot; J Durrel; F Dellatolas; J Duchier
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Early effects of oral administration of omeprazole and roxatidine on intragastric pH.

Authors:  Hiroshi Iida; Shingo Kato; Yusuke Sekino; Eiji Sakai; Takashi Uchiyama; Hiroki Endo; Kunihiro Hosono; Yasunari Sakamoto; Koji Fujita; Masato Yoneda; Tomoko Koide; Hirokazu Takahashi; Chikako Tokoro; Ayumu Goto; Yasunobu Abe; Noritoshi Kobayashi; Kensuke Kubota; Eiji Gotoh; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

3.  Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.

Authors:  M S Ching; G W Mihaly; P W Angus; D J Morgan; S Devenish-Meares; N D Yeomans; R A Smallwood
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  The protective role of laparoscopic antireflux surgery against aspiration of pepsin after lung transplantation.

Authors:  P Marco Fisichella; Christopher S Davis; Peter W Lundberg; Erin Lowery; Ellen L Burnham; Charles G Alex; Luis Ramirez; Karen Pelletiere; Robert B Love; Paul C Kuo; Elizabeth J Kovacs
Journal:  Surgery       Date:  2011-10       Impact factor: 3.982

5.  Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

Authors:  Tomohiko Shimatani; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

6.  Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens.

Authors:  L C Baak; J B Jansen; I Biemond; C B Lamers
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

7.  The pathophysiology of peptic ulcer disease.

Authors:  F P Brooks
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

8.  Oral pharmacokinetics of omeprazole.

Authors:  C W Howden; P A Meredith; J A Forrest; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure.

Authors:  C W Howden; C D Payton; P A Meredith; D M Hughes; A I Macdougall; J L Reid; J A Forrest
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 10.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.